- Home
- MURA vs UCL Comparison
MURA vs UCL Comparison
Compare MURA & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- UCL
- Stock Information
- Founded
- MURA 2013
- UCL 2014
- Country
- MURA Ireland
- UCL Hong Kong
- Employees
- MURA N/A
- UCL N/A
- Industry
- MURA
- UCL Telecommunications Equipment
- Sector
- MURA
- UCL Consumer Discretionary
- Exchange
- MURA Nasdaq
- UCL Nasdaq
- Market Cap
- MURA 45.8M
- UCL 47.0M
- IPO Year
- MURA N/A
- UCL 2020
- Fundamental
- Price
- MURA $2.64
- UCL $1.55
- Analyst Decision
- MURA Strong Buy
- UCL
- Analyst Count
- MURA 4
- UCL 0
- Target Price
- MURA $13.00
- UCL N/A
- AVG Volume (30 Days)
- MURA 190.3K
- UCL 81.5K
- Earning Date
- MURA 05-14-2025
- UCL 05-21-2025
- Dividend Yield
- MURA N/A
- UCL N/A
- EPS Growth
- MURA N/A
- UCL N/A
- EPS
- MURA N/A
- UCL 0.09
- Revenue
- MURA N/A
- UCL $92,256,000.00
- Revenue This Year
- MURA $34.35
- UCL $4.93
- Revenue Next Year
- MURA N/A
- UCL N/A
- P/E Ratio
- MURA N/A
- UCL $18.01
- Revenue Growth
- MURA N/A
- UCL 7.65
- 52 Week Low
- MURA $0.95
- UCL $0.80
- 52 Week High
- MURA $4.74
- UCL $3.30
- Technical
- Relative Strength Index (RSI)
- MURA 51.80
- UCL 60.53
- Support Level
- MURA $2.56
- UCL $1.50
- Resistance Level
- MURA $2.72
- UCL $1.90
- Average True Range (ATR)
- MURA 0.14
- UCL 0.15
- MACD
- MURA -0.02
- UCL 0.02
- Stochastic Oscillator
- MURA 33.33
- UCL 45.75
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.